市場調查報告書
商品編碼
1541515
2024-2032 年口乾症治療市場報告(按類型、藥物類型、配銷通路和地區)Xerostomia Therapeutics Market Report by Type, Drug Type, Distribution Channel, and Region 2024-2032 |
2023年,IMARC Group口乾症(口乾症)治療市場規模達7.398億美元。 % 。
口乾症或口乾是指口腔乾燥的症狀或感覺,通常是由於唾液量減少引起的。這種情況是由頸部和頭部放射性的不利影響、抗焦慮藥物的消耗增加、脫水、糖尿病和阿茲海默症引發的。可以透過唾液筆或興奮劑、人工唾液、處方藥物和家庭療法(包括喝水和滋潤嘴唇)來治療。除此之外,醫生對唾液腺的早期診斷和使用推薦的口腔保濕產品(例如非處方(OTC)漱口水)可以幫助潤滑口腔。這些治療可緩解不適,預防嚴重併發症,修復味覺障礙,並減輕口臭和味覺障礙。因此,一些醫院和診所使用口乾療法來治療唾液腺功能下降。
由於放射治療和化療的藥物副作用,口乾的發生率不斷增加,特別是在老年人群中,以及對口乾緩解產品的需求不斷增加,主要推動了市場的成長。此外,一些處方牙膏、維生素軟糖和治療乾燥綜合症、阿茲海默症和導致口乾症的人類免疫缺陷病毒 (HIV) 的藥物的使用量不斷增加,也是另一個生長誘導因素。與此一致的是,消費者對口乾症早期診斷意識的不斷提高、醫療保健支出的顯著增加以及多樣化診斷技術的出現正在推動市場成長。此外,政府為提高消費者對口乾症及其症狀、原因和治療的認知而採取的有利舉措正在推動市場成長。除此之外,各種治療藥物的容易取得以及持續的研發(R&D)活動正在為市場創造積極的前景。
The global xerostomia (dry mouth disease) therapeutics market size reached US$ 739.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 985.0 Million by 2032, exhibiting a growth rate (CAGR) of 3.13% during 2024-2032.
Xerostomia, or dry mouth, refers to symptoms or sensations of oral dryness that are usually caused due to a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, and Alzheimer's disorder. It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. Apart from this, the early diagnosis of salivary glands by practitioners and the usage of recommended mouth moisturizing products, such as over-the-counter (OTC) rinsing, can assist in lubricating the mouth. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, and mitigate bad breath and taste disorders. Consequently, xerostomia therapeutics are used across several hospitals and clinics to deal with decreased salivary gland function.
The increasing incidences of dry mouth, especially amongst the geriatric population, due to medicine side-effects of radiotherapy and chemotherapy and the rising need for dry mouth relief products are primarily driving the market growth. Additionally, the growing uptake of several prescription-based toothpaste, vitamin gummies, and medicines for treating Sjogren's syndrome, Alzheimer's diseases, and human immunodeficiency virus (HIV) that cause xerostomia is acting as another growth-inducing factor. In line with this, the rising consumer awareness regarding the early diagnosis of xerostomia, significant enhancements in healthcare expenditure, and the advent of diverse diagnostic technologies are propelling the market growth. Moreover, the favorable initiatives being commenced by governments to sensitize consumers regarding the xerostomia disease, its symptoms, causes, and treatments are impelling the market growth. Apart from this, the easy availability of various therapeutic drugs and ongoing research and development (R&D) activities are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global xerostomia (dry mouth disease) therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug type and distribution channel.
Artificial Saliva/Saliva Substitutes
Salivary Stimulants
OTC
Prescription
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).